Search results
Showing 1651 to 1665 of 8910 results
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development Reference number: GID-TA10089 Expected publication date: 15 November 2017
In development Reference number: GID-TA10205 Expected publication date: TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development Reference number: GID-DG10038 Expected publication date: TBC
Awaiting development Reference number: GID-QS10103 Expected publication date: TBC
Awaiting development Reference number: GID-QS10106 Expected publication date: TBC
In development Reference number: GID-QS10113 Expected publication date: TBC
Vulnerable populations: strategies for tackling inequalities
Awaiting development Reference number: GID-QS10124 Expected publication date: TBC
Awaiting development Reference number: GID-QS10129 Expected publication date: TBC
Awaiting development Reference number: GID-QS10130 Expected publication date: TBC